Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Excitatory and Inhibitory Effects of Neurotransmitters01:29

Excitatory and Inhibitory Effects of Neurotransmitters

When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of specific...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toward a Pluralistic Model for the Schizophrenia Spectrum-Dopamine and Beyond.

JAMA psychiatry·2026
Same author

The Future of <i>DSM</i>: Response to Letters.

The American journal of psychiatry·2026
Same author

Distinct Connectivity Signatures of Hallucinatory Experiences and Neuromelanin Signal in Adolescents.

medRxiv : the preprint server for health sciences·2026
Same author

Hydrogen Gas Therapy in Schizophrenia: Potential Neuroprotective Effects From an Animal Study.

Neuropsychopharmacology reports·2026
Same author

The Future of <i>DSM</i>: Role of Candidate Biomarkers and Biological Factors.

The American journal of psychiatry·2026
Same author

Initial Strategy for the Future of <i>DSM</i>.

The American journal of psychiatry·2026

Related Experiment Video

Updated: Jun 5, 2026

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

Presynaptic dopamine in schizophrenia.

Nobumi Miyake1, Judy Thompson, Mette Skinbjerg

  • 1Department of Psychiatry, Columbia University, New York State Psychiatric Institute, New York, NY, USA.

CNS Neuroscience & Therapeutics
|January 5, 2011
PubMed
Summary
This summary is machine-generated.

Schizophrenia involves dysregulated presynaptic dopamine (DA) transmission, leading to excessive striatal DA release. This hyperactivity is linked to psychotic symptoms and treatment response, highlighting its importance for future drug development.

More Related Videos

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology
07:25

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology

Published on: March 27, 2018

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

Related Experiment Videos

Last Updated: Jun 5, 2026

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology
07:25

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology

Published on: March 27, 2018

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

Area of Science:

  • Neuroscience
  • Psychiatry
  • Radiology

Background:

  • Presynaptic dopamine (DA) transmission is crucial for understanding schizophrenia.
  • Previous research has employed various methods to estimate presynaptic dopaminergic neuron integrity and activity.

Purpose of the Study:

  • To investigate presynaptic dopaminergic dysregulation in schizophrenia using advanced imaging techniques.
  • To assess the relationship between DA release and D2 receptor occupancy at baseline.

Main Methods:

  • Utilized [(18)F]DOPA for DA synthesis capacity (dopa decarboxylase activity).
  • Employed stimulant challenges and D2 receptor radiotracer binding to measure DA release and D2 baseline occupancy.
  • Assessed DA and vesicular monoamine transporters for presynaptic terminal integrity.

Main Results:

  • Convergent evidence from imaging modalities indicates dysregulated presynaptic dopaminergic activity in schizophrenia.
  • Demonstrated excessive DA release in the striatum, particularly in associative striatal projections.
  • Linked excessive striatal presynaptic DA to acute psychotic symptoms and treatment response.

Conclusions:

  • Presynaptic dopaminergic dysregulation, specifically excessive striatal DA release, is a key feature of schizophrenia.
  • Understanding this dysregulation is vital for developing novel therapeutic strategies.
  • Further research into the etiology and circuit consequences of this hyperactivity is warranted for future drug development.